Figure 1.

Evaluation of Gene-Silencing Effect of VEGF-siRNA In Vitro

(A and C) B16F10 cells and (B and D) LLC cells were treated with VEGF-siRNA, non-target siRNA, or transfection reagent alone. (A and B) Concentrations of VEGF protein in culture supernatant fluid obtained from B16F10 (A) or LLC (B) cells were measured by enzyme-linked immunosorbent assay (n = 8/group). (C and D) VEGF-A mRNA levels in the cells obtained from B16F10 (C) or LLC (D) cells normalized to beta-actin levels were quantified by real-time RT-PCR (n = 3–4/group). p was determined using the Wilcoxon rank-sum test. *p < 0.05, **p < 0.01 between two groups. N.S., not significant. Bars denote the median values.